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Nanotechnology holds many advantages. Here we report another advantage of applying RNA 
nanotechnology for directional control. The orientation of arrow-shaped RNA was altered to 
control ligand-display on extracellular vesicle (EV) membranes for specific cell targeting, or to 
regulate intracellular trafficking of siRNA/miRNA. Placing membrane-anchoring cholesterol at the 
arrow-tail results in display of RNA aptamer or folate on EV outer surface. In contrast, placing the 
cholesterol at the arrow-head results in partial loading of RNA nanoparticles into the EVs. Taking 
advantage of the RNA ligand for specific targeting and EVs for efficient membrane fusion, the 
resulting ligand-displaying EVs were competent for specific delivery of siRNA to cells, and 
efficiently block tumor growth in three cancer models. PSMA aptamer-displaying EVs loaded with 
survivin siRNA inhibited prostate cancer xenograft. The same EV but displaying EGFR aptamer 
inhibited orthotopic breast cancer models. Likewise, survivin-loaded and folate-displaying EVs 
inhibited patient derived colorectal cancer xenograft.
Design and construction of arrow-shaped RNA nanostructures
The three-way junction (3WJ)1, 2 of the bacteriophage phi29 motor pRNA3, 4 folds by its 
intrinsic nature into a planar arrangement with three angles of 60°, 120°, and 180° between 
helical regions (Fig. 1a–b).2 The pRNA-3WJ was extended into an arrow-shaped structure 
by incorporating an RNA aptamer serving as a targeting ligand for binding to specific 
receptors overexpressed on cancer cells. The engineered pRNA-3WJ was used to decorate 
EVs purified from HEK293T cell culture supernatants to create ligand-decorated EVs. 
HEK293T EVs were used as they contain minimal intrinsic biological cargos compared to 
EVs generated by other cells.5 As shown in Western blots (Fig. S1a), HEK293T isolated 
EVs showed negative staining for several common integrin markers as seen on EVs for 
cancerous origins,6, 7 with only positive staining for TSG101. Additional steps were taken to 
remove EVs from FBS used in the HEK293T cell culture; although, centrifugation might not 
completely remove the FBS EVs.8, 9 Ultracentrifugation using OptiPrep was used to purify 
EVs (see Methods).10 The addition of iso-osmotic OptiPrep cushion layer greatly enhanced 
reproducibility of EVs purification in purity (Fig. S1c), and also minimized physical 
disruption of EVs by ultracentrifugation pelleting as shown by Electron Microscopy (EM) 
imaging (Fig. 1c). The presence of the OptiPrep cushion layer did not change the EVs 
particle size distribution or zeta potential significantly (Fig. 1d–e), but rather preserved the 
native shape of EVs. The EVs purified without the OptiPrep cushion appear as flattened 
spheres (Fig. 1c right), while the majority of EVs purified with the cushion appear as full 
spheres (Fig. 1c left). The size of EVs from EM image might not always represent its 
particle size distribution in the population. Nanoparticle Tracking Analysis (NTA) and 
Dynamic Light Scattering (DLS) revealed that the isolated native EVs were physically 
homogeneous, with a narrow size distribution centered around 96 nm (Fig. 1d) and a 
negative zeta potential (Fig. 1e). The purified EVs were further identified by the presence of 
EV specific marker TSG10111 by Western blot (Fig. S1a). The yield of purified EVs from 
HEK293T cell culture supernatant was about 10–15 μg (measured as protein concentration), 
or 0.1 ‒ 1.9×109 EV particles (measured by NTA) per 106 cells. A single steroid molecule, 
cholesterol-triethylene glycol (TEG), was conjugated into the arrow-tail of the pRNA-3WJ 
to promote the anchorage of the 3WJ onto the EV membrane (Fig. 1b). Cholesterol 
spontaneously inserts into the membrane of EVs via its hydrophobic moiety.12, 13 Display of 
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RNA nanoparticles on surface of purified EVs was achieved by simply incubating the 
cholesterol-modified RNA nanoparticles with EVs at 37 °C for one hour.
EVs hold great promise as emerging therapeutic carriers given their role in intercellular 
communication. They can enter cells through multiple routes including membrane fusion, 
tetraspanin and integrin receptor-mediated endocytosis, lipid raft mediated endocytosis, or 
micropinocytosis. However, there is limited specificity regarding the recipient cells.14, 15 In 
order to confer specific targeting of EVs to cancer cells, three classes of targeting ligands, 
folate, PSMA RNA aptamer, or EGFR RNA aptamer were conjugated to the 3WJ for 
displaying on the EVs surface. Folate is an attractive targeting ligand since many cancers of 
epithelial origin, such as colorectal cancers, overexpress folate receptors.16 PSMA is 
expressed at an abnormally high level in prostate cancer cells, and its expression is also 
associated with more aggressive diseases.17 A PSMA-binding 2′-Fluoro (2′-F) modified 
RNA aptamer A9g18, 19 was displayed on EVs to enhance targeting efficiency to prostate 
cancer cells. The PSMA aptamer A9g is a 43-mer truncated version of A9, which binds 
PSMA specifically with Kd 130nM18 and used as RNA based ligand. EGFR is highly 
overexpressed in triple negative breast cancer (TNBC) tumors and metastatic TNBC 
tumors.20 An EGFR specific 2′F-RNA aptamer21, 22 was incorporated to one end of 
pRNA-3WJ and thereby displayed on EVs for enhanced targeting of breast cancer cells. For 
imaging, one of the pRNA-3WJ strands was end-labeled with a fluorescent dye Alexa647 
(Fig. 1h). The size distribution and zeta potential of RNA nanoparticle-decorated EVs did 
not change significantly compared with native EVs as measured by NTA and DLS (Fig. 1f–
g).
Survivin, an inhibitor of cell apoptosis, is an attractive target for cancer therapy, since its 
knockdown can decrease tumorigenicity and inhibit metastases.23, 24 In combination with 
the survivin siRNA loaded in the EVs (Fig. 1i), siRNA loaded EVs with targeting moieties 
were prepared to evaluate in vivo prostate, breast, and colon cancer inhibition efficacy (see 
section 5). To improve the stability of siRNA in vivo, the passenger strand was 2′-F 
modified on pyrimidines to provide RNase resistance, while the guide strand was kept 
unmodified.25, 26 For tracking siRNA loading efficiency in EVs, the survivin siRNA was 
fused to an Alexa647-labeled 3WJ core and assembled into RNA nanoparticles (Fig. S1b). 
After loading siRNA into EVs and decorating EVs with PSMAapt/3WJ/Cholesterol RNA 
nanoparticles, there was not a significant change in the EVs size, as measured by NTA with 
two peaks at 103 and 120 nm (Fig. 1f). Treating survivin-3WJ RNA nanoparticles in PBS 
with ExoFect, without EVs, showed a different particle size distribution profile (PBS/
siSurvivin) and about 40-times lower particle concentration (Fig. S1e). The loading 
efficiency for siRNA-3WJ RNA nanoparticles was around 70% (Fig. S1d) as measured by 
fluorescent intensity of the free RNA nanoparticles. Controls without EVs or with only the 
ExoFect reagent showed as low as 15% pelleting.
Arrow-head or arrow-tail for RNA loading or membrane display
Serum digestion assay was used to differentiate between entry and surface display on EVs. 
The orientation and angle of the arrow-shaped pRNA-3WJ nanostructure was used to control 
RNA loading or surface display of EVs. Serum digestion was performed to confirm the 
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localization of 2′-F RNA nanoparticles with EVs. Although 2′-F 3WJ RNA nanoparticles 
are relatively resistant to RNaseA (Fig. S2a), they can be digested in 67 % fetal bovine 
serum (FBS) and incubated at 37 °C for 2 hours (Fig. S2b). Alexa647-2′F RNA nanoparticle-
displaying EVs were purified from free RNA nanoparticles by ultracentrifugation, then 
subjected to serum digestion. Alexa647-2′F RNA with cholesterol on the arrow-tail for EVs 
decoration were degraded (31.6 ± 8.8 %) much more than the arrow-head cholesterol-
decorated counterparts (9.5 ± 11.9 %) after 37 °C FBS incubation (Fig. 2a–d). These results 
indicate that cholesterol on the arrow-tail promoted display of either folate-3WJ or RNA 
aptamers on the surface of the EVs and were therefore degraded. While cholesterol on the 
arrow-head promoted RNA nanoparticles entering EVs, as evidenced by the protection of 
the Alexa647-2′F RNA nanoparticles against serum digestion. In the arrow-tail 
configuration, it seems as if the two arms that form a 60° angle can act as a hook to lock the 
RNA nanoparticle in place. If this was the case, the effect would prevent the hooked RNA 
from passing through the membrane (Fig. 2a). The concentration of FBS used in the serum 
digestion experiment was kept extremely high purposefully to degrade the externally 
displayed RNA on EVs. The decorated PSMAapt-3WJ 2′F RNA nanoparticles have been 
shown to remain stable and intact under physiological conditions.19, 22
Competition assay was used to differentiate between entry and surface display on EVs. As 
described above, when cholesterol was attached to the arrow-tail of pRNA-3WJ, the RNA 
nanoparticles were anchored on the membrane of EVs, and the incorporated ligands were 
displayed on the outer surface of the EVs (Fig. 2a). An increase in the binding of EVs to 
folate receptor-overexpressing KB cells was detected by displaying folate on the EV surface 
using arrow-tail cholesterol RNA nanoparticles (Fig. 2e,f). When incubating with low folate 
receptor-expressing MDA-MB-231 breast cancer cells, arrow-tail-shaped FA-3WJ/EV did 
not enhance its cell binding compared to arrow-tail ligand free 3WJ/EV (Fig. 2g). The 
surface display of folate was further confirmed by free folate competition assay, in which a 
baseline of binding by the cholesterol arrow-tail FA-3WJ/EVs to KB cells was established. 
A decrease (48.3 ± 0.6 %) in the cellular binding to KB cells was detected when 10 μM of 
free folate was added to compete with the cholesterol-arrow-tail FA-3WJ/EV for folate 
receptor binding (Fig. 2f). In contrast, competition by free folate in arrow-head FA-3WJ/EV 
(Fig. 2h) binding to KB cells was much lower (24.8 ± 0.6 %) (Fig. 2i), which is possibly due 
to partial internalization of the arrow-head-shaped FA-3WJ nanoparticle into the EVs, which 
resulted in a lower display intensity of folate on the surface of the EVs.
EVs can mediate intercellular communication by transporting mRNA, siRNA, miRNA or 
proteins and peptides between cells. They internalize into recipient cells through various 
pathways, including micropinocytosis, receptor-mediated endocytosis, or lipid raft-mediated 
endocytosis.14 Although the natural process for the uptake of EVs is not ligand-dependent, 
the arrow-tail cholesterol RNA-3WJ allows for displaying ligand onto the surface of EVs, 
and increasing its targeting efficiency to the corresponding receptor overexpressing cancer 
cells.
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Cancer-targeting and gene silencing of RNA-displaying EVs
Specific cancer cell-targeting is an important prerequisite for applying nano-vesicles to 
cancer therapy. To generate cancer cell-targeting EVs, approaches to express cancer cell-
specific ligands on EVs have been explored. One way to increase the specificity of EVs to 
target cells is to overexpress peptide ligands fused to EV membrane proteins.27 Neuron 
acetylcholine receptor specific peptide RVG has been fused to EV membrane protein 
Lamp2b to be overexpressed on dendritic cells.27 GE11 peptide, which is a ligand to EGFR 
(Epidermal Growth Factor Receptor), was fused to the transmembrane domain of the 
platelet-derived growth factor receptor to be overexpressed on EV donor HEK293T cells.28 
RGD peptide was fused to EV protein Lamp2b; thus, the EVs can deliver the chemical drug 
doxorubicin specifically to tumor cells.29 One problem in using fusion peptide for targeted 
exosomal delivery is that the displayed peptide can be degraded during EV biogenesis.30 We 
explored a method of displaying ligands onto the EVs surface post-biogenesis to enhance its 
specificity.
The targeting, delivery and gene silencing efficiency of the PSMA aptamer displaying EVs 
were examined in PSMA-positive LNCaP prostate cancer cells. To confer RNase resistance, 
2′-F modifications were applied to the RNA nanoparticles placed on the surface of EVs,1 
while the thermodynamic stability of pRNA-3WJ provided a rigid structure to ensure the 
correct folding of RNA aptamers.1, 31 PSMA aptamer-displaying EVs showed enhanced 
binding and apparent uptake to PSMA(+) LNCaP cells compared to EVs without PSMA 
aptamer by flow cytometry and confocal microscopy analysis, but not to the PC-3 cells, 
which is a low PSMA receptor expressing cell line (Fig. 3a). Upon incubation with LNCaP 
cells, PSMAapt/EV/siSurvivin was able to knock down the survivin expression at the mRNA 
level as demonstrated by real-time PCR (37.73 ± 11.59%, p<0.05) (Fig. 3b) and protein level 
as shown by Western Blot (62.89 ± 8.5 %, p<0.05) (Fig. S3). Cell viability by MTT assays 
indicated that the viability of LNCaP cells were decreased as a result of survivin siRNA 
delivery (70.98 ± 6.46 %, p<0.05) (Fig. 3c).
The ligand displaying EVs target tumors
The tumor targeting and biodistribution properties of ligand-displaying EVs were evaluated. 
FA-3WJ/EVs were systemically administered via the tail vein into KB subcutaneous 
xenograft mice model. 3WJ/EVs and PBS treated mice were tested as a control. Ex vivo 
images of healthy organs and tumors taken from mice after 8 hrs showed that the 
FA-3WJ/EVs mainly accumulated in tumors, with low accumulation in vital organs in 
comparison with PBS control mice, and with more accumulation in tumors in comparison 
with 3WJ/EVs control mice (Fig. 4a). Normal EVs without surface modification usually 
showed accumulation in liver after systemic delivery.28 Both RNA and cell membranes are 
negatively charged. The electrostatic repulsion effect has been shown to play a role in 
reducing the accumulation of RNA nanoparticles in healthy organs.19, 22, 32 We hypothesize 
that displaying targeting RNAs on the EVs surface reduces their accumulation in normal 
organs, and the ideal nano-scale size of RNA displaying EVs facilitates tumor targeting via 
Enhance Permeability and Retention (EPR) effects, thereby avoiding toxicity and side 
effects.
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Inhibition of tumor growth by ligand-3WJ-displaying EVs
The PSMA aptamer displaying EVs completely inhibits prostate cancer growth in mice. The 
therapeutic effect of PSMA aptamer-displaying EVs for prostate cancer treatment was 
evaluated using LNCaP-LN3 tumor xenografts.33, 34 Treatment with PSMAapt/EV/
siSurvivin (1 dose every 3 days; total 6 doses) completely suppressed in vivo tumor growth, 
compared to control groups (Fig. 4b). EVs are biocompatible and well tolerated in vivo, we 
did not observe any significant toxicity as indicated by body weights of the mice, assessed 
over 40 days post-treatment (Fig. 4c). Analyzing the survivin mRNA expression levels in the 
tumor by real time PCR using GAPDH as internal control showed a trend of knocking down 
survivin by PSMAapt/EV/siSurvivin (Fig. 4d). Taken together, PSMA aptamer displaying 
EVs is a promising vector for delivering survivin siRNA in vivo and systemic injection of 
PSMAapt/EV/siSurvivin might achieve desired therapeutic efficacy.
The in vivo cancer growth inhibition effect was more pronounced than in vitro MTT assays 
in prostate cancer studies. The displaying of PSMA aptamer on the surface of EVs slightly 
enhanced its targeting to PSMA receptor overexpressing cancer cells in vitro, while the 
negatively charged RNA on EV surface might have minimized its nonspecific distribution to 
healthy cells as seen in the FA-3WJ/EVs biodistribution test. The EPR effect could also 
promote the homing of nanoscale EVs into tumors in vivo; although the biodistribution 
presented in Fig. 4a may not apply to the functional evaluation presented in Fig. 4b. All 
these results suggest that RNA aptamer displaying EVs are suitable for in vivo applications.
The EGFR aptamer displaying EVs inhibited breast cancer growth in mice. Overexpression 
of EGFR in breast cancer cells is associated with high proliferation, and risk of relapse in 
patients receiving treatment.35 We constructed pRNA-3WJ nanoparticles harboring EGFR 
aptamer (Fig. S4a) for display on EV surface and loaded the EVs with survivin siRNA. The 
resulting EGFRapt/EV/siSurvivin particles were administered via tail vein into the MDA-
MB-468 orthotopic xenograft tumor bearing mice. 3WJ/EV/siSurvivin (without targeting 
ligand) and PBS treated mice served as controls. The analysis was completed with three 
mice per group. Ex vivo images taken after 8 hrs showed that the EGFRapt/EV/siSurvivin 
accumulated more in tumors than the control groups (Fig. 5a), indicating that displaying 
EGFR aptamer on the surface of EVs greatly enhanced its tumor targeting capabilities in 
vivo. Treatment with EGFRapt/EV/siSurvivin at a dose of 0.5 mg siRNA/kg of mice body 
weight (6 doses weekly) significantly suppressed in vivo tumor growth as monitored by 
tumor volume, compared to controls (Fig. 5b). The specific knockdown of survivin was 
validated from three representative tumors from each group by both Western blot (Fig. 5c) 
and quantitative real-time PCR (Fig. 5d), where GAPDH was used as an internal 
normalization control. The results indicate that successful delivery of survivin siRNA to 
breast tumor cells inhibited survivin expression at both protein and mRNA levels.
Folate displaying EVs inhibited colorectal cancer growth in mice. Survivin gene, an anti-
apoptotic protein, is upregulated in most colorectal cancers, as tested by 
immunohistochemistry (IHC) imaging of tumor tissues from 9 colorectal cancer patients 
(Fig. S5). Utilizing a similar strategy, we constructed pRNA-3WJ nanoparticles harboring 
folate (Fig. S4b) for display on EV surface and loaded the EVs with survivin siRNA. The 
Pi et al. Page 6
Nat Nanotechnol. Author manuscript; available in PMC 2018 June 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
functionalized EVs were then evaluated in a clinically relevant patient derived CRC 
xenograft (PDX-CRC) mouse model. Treatment with FA/EV/siSurvivin at a dose of 0.5 mg 
siRNA/kg of mice body weight (6 doses weekly) significantly suppressed in vivo tumor 
growth as measured by tumor volume and tumor weight, compared to control group (Fig. 
6a–b). The data suggests that folate displaying EVs can be used as a vector for delivering 
siRNA for colorectal cancer treatment.
The application of RNA interference technology, such as siRNA, to knockdown gene 
expression has been of great interest.36 The nanometer-scale EVs37–40 can deliver 
biomolecules into cells by direct fusion with the cell membrane through tetraspanin 
domains, or back-fusion with endosomal compartment membranes for endosome escape. 
Therapeutic payloads, such as siRNA, can fully function after delivery to cells by EVs.37–40 
However, EVs lack selectivity and can also randomly fuse to healthy cells. To generate 
specific cell-targeting EVs, approaches by in vivo expression of cell specific peptide ligands 
on the surface of EVs have been explored.27, 28 However, in vivo expression of protein 
ligands is limited to the availability of ligands in their producing cell types.37, 40,41 It would 
be desirable for in vivo cancer cell targeting using in vitro surface display technology to 
display nucleic acid-based or chemical targeting ligands on EVs.
This article reports the in vitro application of RNA nanotechnology42 to reprogram natural 
EVs for specific delivery of siRNA to cancer models in vitro and in animal models (Fig. 1a–
c). Taking advantage of the thermodynamically stable properties of pRNA-3WJ,1, 31, 43 
multifunctional RNA nanoparticles harboring membrane-anchoring lipid domain, imaging 
modules and targeting modules were generated. The arrow-shaped pRNA-3WJ offered the 
opportunity to control either partial loading of RNA into EVs or decoration of ligands on the 
surface of EVs. With cholesterol placed on the arrow-tail of the 3WJ, the RNA-ligand was 
prevented from trafficking into EVs, ensuring oriented surface display of targeting modules 
for cancer receptor binding. This was explicitly demonstrated by serum digestion and folate 
competition assays (Fig. 2f), as well as by enhanced binding to LNCaP cells after PSMA 
aptamer display (Fig. 3a) and during in vivo breast cancer by the EGFR aptamer display 
(Fig. 5a). Additionally, the placement of cholesterol on the arrow-head allowed for partial 
internalization of the RNA nanoparticle within the EVs (Fig. 2b, h). The incorporation of 
arrow-tail 3WJ-RNA nanoparticles to the surface of the EVs not only provided a targeting 
ligand to the EVs, but also added a negative charge on the EVs surface. Displaying 
negatively charged RNA nanoparticles on EV surface might assist in the reduction of non-
specific binding of EV to normal cells. We have noticed previously that negatively charged 
RNA nanoparticles with a proper ligand tend to accumulate into tumors specifically after 
systemic administration.19, 22, 32 The cholesterol-TEG-modified RNA nanoparticles should 
preferentially anchor onto the raft-forming domains of the lipid bilayer of EVs,12 and further 
studies will be necessary to illustrate this process. EVs have the intrinsic ability to back-fuse 
with endosomal compartment membranes following receptor mediated endocytosis.37–39 
Our in vitro decoration approach preserved the favorable endogenous composition of EVs as 
delivery vectors, thus eliminating the need to build artificial endosome-escape strategies into 
the EV vectors compared to using other synthetic nanovectors for siRNA delivery.44, 45
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CONCLUSION
This study demonstrates the effective reprogramming of native EVs using RNA 
nanotechnology. RNA nanoparticles orientation was used to controls siRNA and miRNA 
loading or surface display on EVs for efficient cell targeting, siRNA and miRNA delivery 
and cancer regression. The reprogrammed EVs displayed robust physiochemical properties, 
enhanced cancer cell specific targeting, and efficient intracellular release of siRNA to 
suppress tumor growth in three animal models.
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Figure 1. RNA nanotechnology for decorating native EVs
(a) AFM image of extended 3WJ of the motor pRNA of bacteriophage phi29. (b) Illustration 
of the location for cholesterol labeling of the arrow-head or arrow-tail of 3WJ. (c) Negative-
stained EM image of EVs from HEK293T cells purified with differential ultracentrifugation 
method and cushion modified ultracentrifugation method. (d–g) NTA for size analysis and 
DLS for Zeta potential measurements. (h) 2D structure (left panel) and native PAGE for 
testing 3WJ assembly from three component strands, as indicated. (i). EVs loading and RNA 
aptamer display.
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Figure 2. Comparison of the role between arrow-head and arrow-tail 3WJ
(a–b) Illustration showing the difference between arrow-head and arrow-tail display. (c) 
Syner gel to test arrow-head and arrow-tail Alexa647-3WJ/EV degradation by RNase in FBS. 
The gel was imaged at Alexa647 channel (d) and the bands were quantified by Image J. (e–i) 
Assay to compare cell binding of folate-3WJ arrow-tail (e–g) and arrow-head (h–i) on folate 
receptor positive and negative cells.
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Figure 3. Specific binding and siRNA delivery to cells in vitro using PSMA aptamer-displaying 
EVs
(a) Flow cytometry (left) and confocal images (right) showing the binding of PSMA RNA 
aptamer-displaying EVs to PSMA-receptor positive and negative cells. Nucleus (Blue), 
cytoskeleton (Green), and RNA (Red) in confocal images. (b) RT-PCR assay for PSMA 
aptamer-mediated delivery of survivin siRNA by EVs to PSMA(+) prostate cancer cells. 
Statistics: n=4; experiment was run in four biological replicates and two to four technical 
repeats with an ANOVA analysis; holm adjusted p = 0.0120, 0.0067 comparing 
PSMAapt/EV/siSurvivin to PSMAapt/EV/siScramble and 3WJ/EV/siSurvivin, respectively. 
(c) MTT assay showing reduced cellular proliferation. n=3, p = 0.003, 0.031 comparing 
PSMAapt/EV/siSurvivin to PSMAapt/EV/siScramble and 3WJ/EV/siSurvivin respectively. 
*p<0.05, **p<0.01.
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Figure 4. Animal trials using ligands displaying EV for tumor inhibition
(a) Organ images showing specific tumor targeting 8 hrs after systemic injection of folate 
displaying EVs to mice with subcutaneous KB cell xenografts. n = 2, two independent 
experiments. (b) Intravenous treatment of nude mice bearing LNCaP-LN3 subcutaneous 
xenografts with PSMAapt/EV/siSurvivin or PSMAapt/EV/siScramble (both with 0.6 mg/kg, 
siRNA/mice body weight), and PBS, injected twice per week for three weeks. n=10 
biological replicates, 2 independent experiments, and statistics were calculated using a two-
sided t-test expressed as averages and with standard deviation. p = 0.347, 0.6–2, 1.5e–6, 
8.2e–8, 2.1e–7, 1.0e–7, 1.9e–7, 1.8e–6 for days 15, 18, 22, 25, 29, 32, 36, and 39 
respectively for PSMAapt/EV/siSurvivin compared to control. (c) Body weight of mice 
during the time course of EVs treatment. (d) RT-PCR showing the trend of knockdown 
survivin mRNA expression in prostate tumors after EV treatment.
Pi et al. Page 14
Nat Nanotechnol. Author manuscript; available in PMC 2018 June 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. EGFR aptamer displaying EVs can deliver survivin siRNA to breast cancer orthotopic 
xenograft mouse model
(a) EGFR aptamer displaying EVs showed enhanced targeting effect to breast tumor in 
orthotopic xenograft mice models. (b) Intravenous treatment of nude mice bearing breast 
cancer orthotopic xenografts with EGFRapt/EV/siSurvivin and controls (n=5). After 6 
weeks, EGFRapt/EV/siSurvivin treated group had significantly smaller tumor size than other 
controls. p = 0.008 comparing EGFRapt/EV/siSurvivin to EGFRapt/EV/siScramble. (c) 
Analysis of the protein expression in tumor extracts showed that EGFRapt/EV/siSurvivin 
treatment significantly reduced the expression of Survivin. p=0.0004 comparing 
EGFRapt/EV/siSurvivin to EGFRapt/EV/siScramble. (d) Quantitative real-time PCR on 
extracted RNA from tumors showed the reduction of Survivin mRNA in the EGFRapt/EV/
siSurvivin treated mice compared to controls. p=0.024 comparing EGFRapt/EV/siSurvivin to 
EGFRapt/EV/siScramble. Error bars indicate s.e.m. * p < 0.05, ** p < 0.01, *** p<0.001.
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Figure 6. Folate displaying EVs can deliver survivin siRNA to patient derived colorectal cancer 
xenograft (PDX-CRC) mouse model
(a) Intravenous treatment of nude mice bearing PDX-CRC xenografts with FA/EV/
siSurvivin and controls (n=4). After 6 weeks, FA/EV/siSurvivin treated group had 
significantly smaller tumor size, p = 0.0098 and 0.0387 comparing FA/EV/siSurvivin to 
FA/EV/siScramble at week 4 and week 5 respectively. (b) Lower tumor weight than 
controls. p = 0.0024 comparing FA/EV/siSurvivin to FA/EV/siScramble. Error bars indicate 
s.e.m. * p < 0.05, ** p < 0.01.
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